A Phase IIa, Randomised, Double Blind, Placebo Controlled, Three Way Crossover Study to Assess the Pharmacokinetics of RPL554 Administered to Adult Patients With Cystic Fibrosis.
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs RPL 554 (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Verona Pharma
- 27 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
- 27 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.
- 04 Apr 2017 According to a Verona Pharma media release, the company expects to announce top-line data from this trial in the first half of 2018.